Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat

Vincent G. DeMarco, Megan S. Johnson, Javad Habibi, Lakshmi Pulakat, Rukhsana Gul, Melvin R. Hayden, Roger D. Tilmon, Kevin C. Dellsperger, Nathaniel Winer, Adam T. Whaley-Connell, James R. Sowers

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Telmisartan, an angiotensin receptor blocker, may have unique benefits as it possesses partial peroxisome proliferator-activated receptor (PPAR)-γ agonist activity in addition to antihypertensive effects. In this study, we test whether treatment with telmisartan ameliorates cardiovascular abnormalities to a greater extent than olmesartan, which has little PPAR-γ activity. The hypertensive rodent model of tissue renin-angiotensin system activation, transgenic (mRen2)27 (Ren2) rats and their littermate Sprague-Dawley controls were used. Rats were treated with telmisartan (2 mg•kg -1•day-1), olmesartan (2.5 mg•kg -1•day-1), or vehicle via drinking water for 3 wk; these doses achieved similar blood pressure control, as measured by telemetry. Ren2 rats displayed impaired diastolic and systolic function using left ventricular (LV) pressure-volume (P-V) analysis. Load-independent diastolic indexes, including the time constant of isovolumic relaxation and the slope of the end-diastolic P-V relationship, as well as systolic indexes, including preload recruitable stroke work, the dP/dtmax-end-diastolic volume (EDV) relationship, and the P-V area-EDV relationship, were elevated in Ren2 rats compared with Sprague-Dawley controls (P < 0.05). The Ren2 myocardium exhibited parallel increases in the oxidant markers NADPH oxidase and 3-nitrotyrosine. The increase in the prohypertrophic protein Jak2 in Ren2 rats was associated with cardiac structural abnormalities using light microscopic and ultrastructural analysis, which included interstitial fibrosis, cardiomyocyte and LV hypertrophy, and mitochondrial derangements. Both angiotensin receptor blockers attenuate these abnormalities to a similar extent. Our data suggest that the beneficial effect of telmisartan and olmesartan on cardiac structure and function may be predominantly pressor-related or angiotensin type 1 receptor dependent in this model of renin-angiotensin system activation.

Original languageEnglish (US)
Pages (from-to)H181-H190
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume300
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Peroxisome Proliferator-Activated Receptors
Angiotensin Receptor Antagonists
Renin-Angiotensin System
Cardiovascular Abnormalities
Blood Pressure
Telemetry
Angiotensin Type 1 Receptor
NADPH Oxidase
Left Ventricular Hypertrophy
Ventricular Pressure
Cardiac Myocytes
Oxidants
Drinking Water
Antihypertensive Agents
Rodentia
Myocardium
Fibrosis
Stroke
telmisartan
olmesartan

Keywords

  • AMP-activated protein kinase
  • Janus-activated kinase 2
  • Left ventricular hypertrophy
  • Oxidative stress
  • Peroxisome proliferator-activated receptor-γ

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat. / DeMarco, Vincent G.; Johnson, Megan S.; Habibi, Javad; Pulakat, Lakshmi; Gul, Rukhsana; Hayden, Melvin R.; Tilmon, Roger D.; Dellsperger, Kevin C.; Winer, Nathaniel; Whaley-Connell, Adam T.; Sowers, James R.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 300, No. 1, 01.01.2011, p. H181-H190.

Research output: Contribution to journalArticle

DeMarco, VG, Johnson, MS, Habibi, J, Pulakat, L, Gul, R, Hayden, MR, Tilmon, RD, Dellsperger, KC, Winer, N, Whaley-Connell, AT & Sowers, JR 2011, 'Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat', American Journal of Physiology - Heart and Circulatory Physiology, vol. 300, no. 1, pp. H181-H190. https://doi.org/10.1152/ajpheart.00883.2010
DeMarco, Vincent G. ; Johnson, Megan S. ; Habibi, Javad ; Pulakat, Lakshmi ; Gul, Rukhsana ; Hayden, Melvin R. ; Tilmon, Roger D. ; Dellsperger, Kevin C. ; Winer, Nathaniel ; Whaley-Connell, Adam T. ; Sowers, James R. / Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat. In: American Journal of Physiology - Heart and Circulatory Physiology. 2011 ; Vol. 300, No. 1. pp. H181-H190.
@article{80da32c4e75644e889aeb27bf9e5322a,
title = "Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat",
abstract = "Telmisartan, an angiotensin receptor blocker, may have unique benefits as it possesses partial peroxisome proliferator-activated receptor (PPAR)-γ agonist activity in addition to antihypertensive effects. In this study, we test whether treatment with telmisartan ameliorates cardiovascular abnormalities to a greater extent than olmesartan, which has little PPAR-γ activity. The hypertensive rodent model of tissue renin-angiotensin system activation, transgenic (mRen2)27 (Ren2) rats and their littermate Sprague-Dawley controls were used. Rats were treated with telmisartan (2 mg•kg -1•day-1), olmesartan (2.5 mg•kg -1•day-1), or vehicle via drinking water for 3 wk; these doses achieved similar blood pressure control, as measured by telemetry. Ren2 rats displayed impaired diastolic and systolic function using left ventricular (LV) pressure-volume (P-V) analysis. Load-independent diastolic indexes, including the time constant of isovolumic relaxation and the slope of the end-diastolic P-V relationship, as well as systolic indexes, including preload recruitable stroke work, the dP/dtmax-end-diastolic volume (EDV) relationship, and the P-V area-EDV relationship, were elevated in Ren2 rats compared with Sprague-Dawley controls (P < 0.05). The Ren2 myocardium exhibited parallel increases in the oxidant markers NADPH oxidase and 3-nitrotyrosine. The increase in the prohypertrophic protein Jak2 in Ren2 rats was associated with cardiac structural abnormalities using light microscopic and ultrastructural analysis, which included interstitial fibrosis, cardiomyocyte and LV hypertrophy, and mitochondrial derangements. Both angiotensin receptor blockers attenuate these abnormalities to a similar extent. Our data suggest that the beneficial effect of telmisartan and olmesartan on cardiac structure and function may be predominantly pressor-related or angiotensin type 1 receptor dependent in this model of renin-angiotensin system activation.",
keywords = "AMP-activated protein kinase, Janus-activated kinase 2, Left ventricular hypertrophy, Oxidative stress, Peroxisome proliferator-activated receptor-γ",
author = "DeMarco, {Vincent G.} and Johnson, {Megan S.} and Javad Habibi and Lakshmi Pulakat and Rukhsana Gul and Hayden, {Melvin R.} and Tilmon, {Roger D.} and Dellsperger, {Kevin C.} and Nathaniel Winer and Whaley-Connell, {Adam T.} and Sowers, {James R.}",
year = "2011",
month = "1",
day = "1",
doi = "10.1152/ajpheart.00883.2010",
language = "English (US)",
volume = "300",
pages = "H181--H190",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "1",

}

TY - JOUR

T1 - Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat

AU - DeMarco, Vincent G.

AU - Johnson, Megan S.

AU - Habibi, Javad

AU - Pulakat, Lakshmi

AU - Gul, Rukhsana

AU - Hayden, Melvin R.

AU - Tilmon, Roger D.

AU - Dellsperger, Kevin C.

AU - Winer, Nathaniel

AU - Whaley-Connell, Adam T.

AU - Sowers, James R.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Telmisartan, an angiotensin receptor blocker, may have unique benefits as it possesses partial peroxisome proliferator-activated receptor (PPAR)-γ agonist activity in addition to antihypertensive effects. In this study, we test whether treatment with telmisartan ameliorates cardiovascular abnormalities to a greater extent than olmesartan, which has little PPAR-γ activity. The hypertensive rodent model of tissue renin-angiotensin system activation, transgenic (mRen2)27 (Ren2) rats and their littermate Sprague-Dawley controls were used. Rats were treated with telmisartan (2 mg•kg -1•day-1), olmesartan (2.5 mg•kg -1•day-1), or vehicle via drinking water for 3 wk; these doses achieved similar blood pressure control, as measured by telemetry. Ren2 rats displayed impaired diastolic and systolic function using left ventricular (LV) pressure-volume (P-V) analysis. Load-independent diastolic indexes, including the time constant of isovolumic relaxation and the slope of the end-diastolic P-V relationship, as well as systolic indexes, including preload recruitable stroke work, the dP/dtmax-end-diastolic volume (EDV) relationship, and the P-V area-EDV relationship, were elevated in Ren2 rats compared with Sprague-Dawley controls (P < 0.05). The Ren2 myocardium exhibited parallel increases in the oxidant markers NADPH oxidase and 3-nitrotyrosine. The increase in the prohypertrophic protein Jak2 in Ren2 rats was associated with cardiac structural abnormalities using light microscopic and ultrastructural analysis, which included interstitial fibrosis, cardiomyocyte and LV hypertrophy, and mitochondrial derangements. Both angiotensin receptor blockers attenuate these abnormalities to a similar extent. Our data suggest that the beneficial effect of telmisartan and olmesartan on cardiac structure and function may be predominantly pressor-related or angiotensin type 1 receptor dependent in this model of renin-angiotensin system activation.

AB - Telmisartan, an angiotensin receptor blocker, may have unique benefits as it possesses partial peroxisome proliferator-activated receptor (PPAR)-γ agonist activity in addition to antihypertensive effects. In this study, we test whether treatment with telmisartan ameliorates cardiovascular abnormalities to a greater extent than olmesartan, which has little PPAR-γ activity. The hypertensive rodent model of tissue renin-angiotensin system activation, transgenic (mRen2)27 (Ren2) rats and their littermate Sprague-Dawley controls were used. Rats were treated with telmisartan (2 mg•kg -1•day-1), olmesartan (2.5 mg•kg -1•day-1), or vehicle via drinking water for 3 wk; these doses achieved similar blood pressure control, as measured by telemetry. Ren2 rats displayed impaired diastolic and systolic function using left ventricular (LV) pressure-volume (P-V) analysis. Load-independent diastolic indexes, including the time constant of isovolumic relaxation and the slope of the end-diastolic P-V relationship, as well as systolic indexes, including preload recruitable stroke work, the dP/dtmax-end-diastolic volume (EDV) relationship, and the P-V area-EDV relationship, were elevated in Ren2 rats compared with Sprague-Dawley controls (P < 0.05). The Ren2 myocardium exhibited parallel increases in the oxidant markers NADPH oxidase and 3-nitrotyrosine. The increase in the prohypertrophic protein Jak2 in Ren2 rats was associated with cardiac structural abnormalities using light microscopic and ultrastructural analysis, which included interstitial fibrosis, cardiomyocyte and LV hypertrophy, and mitochondrial derangements. Both angiotensin receptor blockers attenuate these abnormalities to a similar extent. Our data suggest that the beneficial effect of telmisartan and olmesartan on cardiac structure and function may be predominantly pressor-related or angiotensin type 1 receptor dependent in this model of renin-angiotensin system activation.

KW - AMP-activated protein kinase

KW - Janus-activated kinase 2

KW - Left ventricular hypertrophy

KW - Oxidative stress

KW - Peroxisome proliferator-activated receptor-γ

UR - http://www.scopus.com/inward/record.url?scp=78651327296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651327296&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00883.2010

DO - 10.1152/ajpheart.00883.2010

M3 - Article

C2 - 21057043

AN - SCOPUS:78651327296

VL - 300

SP - H181-H190

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 1

ER -